Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus taxane in metastatic breast cancer with HER2-negative primary tumor and HER2-positive circulating tumor cells
NL-OMON46900Phase 2Active, not recruiting
- Sponsor
- Interne Oncologie
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Interne Oncologie. Primary endpoint: Progression-free survival rate at 6 months. Started Mar 2015; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46900.